The National Institute for Health and Care Excellence (NICE) has published new guidance on the treatment oftype 2 diabetes, approving the use of dapagliflozin as triple therapy with metformin and a sulfonylurea where two therapies have failed to achieve adequate glycaemic control.
The guidance means that dapagliflozin joins empagliflozin and canagliflozin as NICE-recommended options for triple therapy.
Professor Carole Longson, director of the NICE Centre for Health technology Evaluation, said having a range of drug options makes it easier to tailor treatments for type 2 diabetes to each person’s individual needs.
A recent study found more patients achieved HbA1C <7% with dapagliflozin (29.4 per cent) versus placebo (12.6 per cent) as add-on to saxagliptin plus metformin. Adverse events were similar with dapagliflozin (66 per cent) and placebo (71 per cent), and hypoglycaemia was rare (≤2%). Genital infections occurred more often with dapagliflozin (6 per cent) than with placebo (1 per cent).
The study concluded that triple therapy with dapagliflozin add-on to saxagliptin plus metformin is a durable, effective and well-tolerated intervention for the treatment of type 2 diabetes.